In order to maximize the value of its innovative compounds, Actelion is entering into product-driven partnerships.

Actelion/Nippon Shinyaku Alliance
Actelion and Nippon Shinyaku entered into an exclusive worldwide alliance in April 2008 to collaborate on an orally available long acting prostaglandin I2 (PGI-2) receptor agonist for patients suffering from pulmonary arterial hypertension. This compound was originally discovered and synthesized by Nippon Shinyaku. Phase I evaluation has recently been completed and a phase II program in PAH patients was initiated by Nippon Shinyaku in Europe at the end of 2007. Actelion will be responsible for global development and commercialization of the PGI-2 receptor agonist outside Japan, whereas the two companies will co-develop and co-commercialize in Japan.

Actelion/Bayer Schering Pharma AG Alliance
Actelion holds the exclusive US rights for inhaled iloprost, sold under the brand name Ventavis®, the only approved inhaled treatment for pulmonary arterial hypertension (PAH), licensed from Bayer Schering Pharma (through the acquisition of CoTherix Inc.,). Actelion holds the US development responsibilities and has established a joint Development and Commercialization Committee for the future collaboration with Bayer Schering Pharma. Actelion books all sales in the US of Ventavis® and pays a royalty on sales to Bayer Schering Pharma AG. In addition to this royalty, Actelion is contractually required to pay one final milestone payment to Bayer Schering Pharma upon achieving a set sales target.  

Actelion/Roche Alliance
Actelion and Roche entered into an exclusive worldwide collaboration in July 2006 to jointly develop and commercialize Actelion’s selective S1P1 receptor agonist, an immunomodulator with the potential for once-a-day oral dosing in patients suffering from autoimmune disorders. The compound is currently being developed in Phase I. The two companies plan to jointly develop and commercialize this novel compound for multiple autoimmune disorders. For the current selective S1P1 receptor agonist, Actelion will fully fund all development activities up to the end of phase II for the first two indications. All subsequent development and commercialization costs will be shared equally between Roche and Actelion. Both companies will co-promote any product resulting from this collaboration and will equally share profit.

Actelion/Merck & Co., Inc. Alliance
Actelion and Merck & Co., Inc. formed an exclusive worldwide alliance in December 2003 to discover, develop and market new classes of orally available renin inhibitors, initially discovered by Actelion, for patients suffering from cardio-renal diseases. Through a joint committee of the Merck Actelion global renin alliance organization, the parties are collaborating on the development of these products. Research and development funding initially will be the responsibility of Actelion. The two companies will jointly fund Phase II development, with Merck responsible for funding all Phase III and outcome studies. Merck will lead and fund commercialization. Actelion retains a worldwide option to co-promote any product resulting from this alliance as a paid-for sales force.